Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function

Neuro-Oncology

Volumn 18, Issue 9, 2016, Pages 1253-1264

  Gielen, Paul R ^a   Schulte, Barbara M ^a   Kers Rebel, Esther D ^a   Verrijp, Kiek ^b   Bossman, Sandra A J F H ^b   Ter Laan, Mark ^b   Wesseling, Pieter ^b,c   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

arginase; glioma; MDSCs; S100A8 9

Indexed keywords

ARGINASE; CALGRANULIN A; CALGRANULIN B; TUMOR MARKER;

CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; MYELOID DERIVED SUPPRESSOR CELL; POLYMERASE CHAIN REACTION; POLYMORPHONUCLEAR CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; BRAIN TUMOR; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; PATHOLOGY; T LYMPHOCYTE; TUMOR CELL CULTURE;

ARGINASE; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CALGRANULIN A; CALGRANULIN B; GLIOBLASTOMA; HUMANS; LYMPHOCYTE ACTIVATION; MYELOID-DERIVED SUPPRESSOR CELLS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 84985982543     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now034     Document Type: Review

References (48)

1. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012; 107(2):359-364.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
3. Grauer OM, Wesseling P, Adema GJ. Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain Pathol. 2009;19(4):674-693.
4. Finocchiaro G, Pellegatta S. Immunotherapy for glioma: getting closer to the clinical arena? Curr Opin Neurol Neurosurg. 2011; 24(6):641-647.
5. Wheeler CJ, Black KL. Vaccines for glioblastoma and high-grade glioma. Expert Rev Vaccines. 2011;10(6):875-886.
6. Wang X, Zhao HY, Zhang FC, Sun Y, Xiong ZY, Jiang XB. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review. Cancer Invest. 2014;32(9):451-457.
7. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105-115.
8. Hanahan D,Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
9. Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol. 2011;2011:732413.
10. Jacobs JF, Idema AJ, Bol KF, et al. Regulatory T cells and the PD-L1/ PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol. 2009;11(4):394-402.
11. Jacobs JF, Idema AJ, Bol KF, et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol. 2010;225(1-2):195-199.
12. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66(6):3294-3302.
13. Gielen PR, Schulte BM, Kers-Rebel ED, et al. Increase in both CD14-Positive and CD15-Positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. J Neuropathol Exp Neurol. 2015;74(5):390-400.
14. Raychaudhuri B, Rayman P, Ireland J, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011;13(6):591-599.
15. Raychaudhuri B, Rayman P, Huang P, et al. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neurooncol. 2015;122(2):293-301.
16. Kohanbash G, McKaveney K, Sakaki M, et al. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-alpha. Cancer Res. 2013;73(21): 6413-6423.
17. Ramachandran IR, Martner A, Pisklakova A, et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol. 2013;190(7):3815-3823.
18. Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008; 205(10):2235-2249.
19. Ghavami S, Rashedi I, Dattilo BM, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol. 2008;83(6): 1484-1492.
20. Vogl T, Gharibyan AL, Morozova-Roche LA. Pro-inflammatory S100A8 and S100A9 proteins: self-assembly into multifunctional native and amyloid complexes. Int J Mol Sci. 2012;13(3):2893-2917.
21. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86(3):557-566.
22. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem. 2002;277(24):21123-21129.
23. de Kok JB, Roelofs RW, Giesendorf BA, et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest. 2005;85(1):154-159.
24. Schulte BM, Gielen PR, Kers-Rebel ED, Schreibelt G, van Kuppeveld FJ, Adema GJ. Enterovirus-infected beta-cells induce distinct response patterns in BDCA1+ and BDCA3+ human dendritic cells. PloS One. 2015;10(3):e0121670.
25. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49-59.
26. Zhang B, Wang Z, Wu L, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PloS One. 2013;8(2):e57114.
27. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011; 60(10):1419-1430.
28. Weide B, Martens A, Zelba H, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1-or melan-A-specific T cells. Clin Cancer Res. 2014;20(6):1601-1609.
29. Jeuken JW, Sijben A, Bleeker FE, et al. The nature and timing of specific copy number changes in the course of molecular progression in diffuse gliomas: further elucidation of their genetic life story. Brain Pathol. 2011;21(3):308-320.
30. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
31. Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol. 2011;4(2):233-242.
32. Varga G, Ehrchen J, Tsianakas A, et al. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol. 2008;84(3):644-650.
33. Liao J, Wang X, Bi Y, et al. Dexamethasone potentiates myeloid-derived suppressor cell function in prolonging allograft survival through nitric oxide. J Leukoc Biol. 2014;96(5):675-684.
34. Wang L, Chang EW, Wong SC, Ong SM, Chong DQ, Ling KL. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol. 2013;190(2):794-804.
35. Feng PH, Lee KY, Chang YL, et al. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med. 2012; 186(10):1025-1036.
36. De Veirman K, Van Valckenborgh E, Lahmar Q, et al. Myeloidderived suppressor cells as therapeutic target in hematological malignancies. Front Oncol. 2014;4:349.
37. Vasquez-Dunddel D, Pan F, Zeng Q, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123(4):1580-1589.
38. Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res. 2006;312(2):184-197.
39. Nemeth J, Stein I, Haag D, et al. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology. 2009;50(4):1251-1262.
40. Deininger MH, Pater S, Strik H, Meyermann R. Macrophage/ microglial cell subpopulations in glioblastoma multiforme relapses are differentially altered by radiochemotherapy. J Neurooncol. 2001;55(3):141-147.
41. Huang N, Chen S, Deng J, et al. Overexpression of S100A9 in human glioma and in-vitro inhibition by aspirin. Eur J Cancer Prev. 2013;22(6):585-595.
42. Li C, Li S, Jia C, Yang L, Song Z, Wang Y. Low concentration of S100A8/9 promotes angiogenesis-related activity of vascular endothelial cells: bridges among inflammation, angiogenesis, and tumorigenesis? Mediators Inflamm. 2012;2012:248574.
43. Turovskaya O, Foell D, Sinha P, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008;29(10):2035-2043.
44. Khammanivong A, Wang C, Sorenson BS, Ross KF, Herzberg MC. S100A8/A9 (calprotectin) negatively regulates G2/M cell cycle progression and growth of squamous cell carcinoma. PloS One. 2013;8(7):e69395.
45. Ghavami S, Kerkhoff C, Chazin WJ, et al. S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DiABLO and Omi/HtrA2. Biochim Biophys Acta. 2008;1783(2):297-311.
46. Zea AH, Rodriguez PC, Culotta KS, et al. L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol. 2004;232(1-2):21-31.
47. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13(2 Pt 2): 721s-726s.
48. Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget. 2014;5(16):6558-6572.